Folina

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Folina

Quick Facts

Feature Detail
Active Ingredient Folic Acid (Vitamin B9)
Pharmacological Class Water-Soluble Vitamin / Hemopoietic Agent
Status Typically Over-the-Counter (OTC) or Prescription (Rx) in high doses
Common Use Treating Folate Deficiency Anemia, Prenatal Supplementation
Form (Brand) Soft Capsules, Tablets, or Oral Solutions

Folina is a brand-name pharmaceutical and nutritional supplement that delivers Folic Acid (also known as Vitamin B9), an essential, water-soluble B vitamin required for key metabolic processes in the human body. As a hemopoietic agent, its primary active ingredient is crucial for the synthesis and maintenance of new cells, particularly the formation of healthy red blood cells.

The medication is most commonly used to prevent and treat conditions arising from a deficiency of folate. This deficiency can lead to a type of anemia called megaloblastic anemia, where red blood cells are abnormally large and immature. Folina is also frequently recommended as a targeted supplement for women who are pregnant or planning to conceive, as Folic Acid is clinically recognized for its essential role in preventing certain major birth defects of the brain and spine (neural tube defects). Due to the time-sensitive nature of fetal development, supplementation is generally advised to begin prior to conception and continue through the first few weeks of pregnancy.

While Folic Acid is the synthetic form of naturally occurring folate found in various foods, Folina provides a concentrated and reliable dosage. For instance, the European brand Folina typically utilizes soft capsules containing 5 mg of Folic Acid, which is a higher therapeutic dose often prescribed to correct a severe deficiency or to address increased needs during certain medical treatments. This formulation makes the compound readily available to the body for the crucial processes of DNA synthesis and repair.

Regulatory References

  1. Neural Tube Defects

What side effects are possible with Folina?

Possible Side Effects and Safety Information

Folic Acid, the active ingredient in Folina, is officially documented as having a generally low potential for toxicity. However, regulatory documents confirm specific adverse reactions and safety constraints associated with its use, particularly at therapeutic doses.

Adverse Reactions by System-Organ Class

The most commonly reported adverse events primarily affect the Gastrointestinal and Psychiatric/Nervous Systems, especially when high doses ( 15 mg daily) are administered. Gastrointestinal effects may include anorexia, nausea, abdominal distention, and flatulence. Psychiatric effects reported in this high-dose context include altered sleep patterns, irritability, confusion, and impaired judgment.

Allergic and Serious Adverse Reactions

Allergic sensitization has been documented, with responses such as skin rash, erythema, and itching reported. More seriously, rare instances of allergic reactions have included symptoms suggesting bronchospasm and potentially anaphylaxis following administration.

Critical Safety Constraints and Population Notes

A critical safety restriction defined in official labeling concerns the risk of masking neurological damage in individuals with undiagnosed Vitamin B12 deficiency (Pernicious Anemia). Folic acid alone may improve blood cell counts, allowing potentially irreversible neurologic damage to progress unchecked. Furthermore, prolonged folic acid therapy may lead to decreased Vitamin B12 serum levels. Folic Acid is officially classified as Pregnancy Category A, indicating that studies in pregnant women have not shown an increased risk of fetal abnormalities.

Overdose and Emergency Response

The official regulatory profile for an overdose of Folina (Folic Acid) establishes that acute toxicity is minimal. Official documentation states that acute overdosage is rarely reported, and even extremely high doses are considered unlikely to cause harm. If acute symptoms occur, they are typically mild and transient, involving non-severe gastrointestinal disturbances such as abdominal distension, flatulence, anorexia, and nausea.

Immediate medical help is required for rare, severe manifestations documented in high-dose scenarios. These include signs of hypersensitivity reactions, such as severe rash, swelling, or the most critical outcome, anaphylactic shock. Regulatory instructions mandate that medical attention must be sought immediately if there is difficulty breathing, swelling of the face or throat, or any other sign indicative of a severe allergic reaction.

No specific antidote is needed for Folic Acid overdose, and treatment is generally described as symptomatic and supportive. A critical regulatory warning underscores that prolonged intake of high doses may mask the hematological signs of an underlying Vitamin B12 deficiency. Failure to address this concomitant deficiency risks severe, irreversible nervous system damage.

Therapeutic Uses of Folina

Folina (Folic Acid) is commonly used to help with managing confirmed deficiencies and associated health outcomes. Folate is required for key cellular processes.

The medication is applied across domains where additional symptomatic support is needed, primarily for correcting folate deficiency that leads to megaloblastic anemia, and for managing the risk of Neural Tube Defects (NTDs). Folina is generally used for managing symptoms related to systemic imbalance like profound physical fatigue, weakness, and lethargy that stem from anemia. This therapy may provide supportive relief that helps maintain functional stability. Furthermore, it contributes to easing the overall symptom load for physical signs of deficiency, such as a sore, inflamed tongue (glossitis) and chronic digestive issues.

“This generally provides support that helps with healthy fetal development during the critical periods of organ formation.”

Quick Fact: Supports Management of Anemia-Related Fatigue and Addresses Mucosal Discomfort

It may help maintain a sense of stability when symptoms are more noticeable and provides supportive relief when symptoms interfere with routine activities.

Regulatory References

  1. MedlinePlus Medical Encyclopedia

Eligibility and Restrictions for Use

Eligibility Scope

Classification Population Eligibility Rules
Populations for whom use is contraindicated Patients with known hypersensitivity to Folic Acid or its excipients. Patients with untreated Vitamin B12 deficiency (Cobalamin deficiency) or undiagnosed megaloblastic anemia [Risk of irreversible neurological damage if administered alone].
Populations requiring restricted or conditional use Patients with malignant disease (cancer) should not use this medicine unless a severe megaloblastic anemia due to folate deficiency is present. Individuals with rare hereditary problems like galactose intolerance (if excipient is included).
Age-related eligibility rules Use is established and permitted for infants, children, adults, and older adults provided the critical deficiency exclusion criteria are met.
Pregnancy and lactation eligibility status Use is permitted and established during pregnancy (for prophylaxis and deficiency states) and lactation, with no reported harmful effects on the fetus or infant.

Eligibility Classifications (High-Level)

Classification Details
Eligibility severity classification Absolute Contraindication for untreated Cobalamin deficiency.
Eligibility-context constraints Use is strictly limited until the cause of anemia is confirmed to exclude a Vitamin B12 deficiency.

Resulting Eligibility Structure

Official eligibility statements:

  • Contraindicated in patients with untreated Cobalamin deficiency.
  • Permitted in all age groups for confirmed folate deficiency.
  • Permitted for use in pregnant and breastfeeding women.
  • Restricted in patients with known malignant disease.

Connection to the overall eligibility profile: Official regulatory documents define eligibility primarily by requiring the exclusion of an underlying Vitamin B12 deficiency to prevent neurological complications. This constraint, along with hypersensitivity, establishes who must not use the medicine, while use in pregnancy is explicitly permitted.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Folina (Folic Acid) interaction patterns are officially documented in relation to effects on other medications' exposure, mutual antagonism, and physical absorption interference.

Drug–Drug Interactions

Anticonvulsant Medications

Folic Acid may reduce the serum levels of certain anticonvulsants, including phenytoin, primidone, and barbiturates. This is officially described as antagonizing the anticonvulsant action.

Folic Acid Antagonists

Folic Acid and co-administered anti-folate agents may have a mutually inhibitory effect. These include medications like methotrexate, trimethoprim, and pyrimethamine. The combination of high-dose Folic Acid with fluorouracil (5-FU) is documented to enhance toxicity.

Absorption Interference

Several agents can interfere with Folic Acid’s absorption or biological response. These include cholestyramine, sulfasalazine, and the antibiotic chloramphenicol.

Administration Timing and Substance Constraints

Official labels require separation for certain co-administered substances. Folic Acid should be taken one hour before or four to six hours after cholestyramine. Similarly, antacids containing aluminum or magnesium should be taken at least two hours after Folic Acid administration. Alcohol consumption is documented to increase Folic Acid elimination. Additionally, Folic Acid may reduce the intestinal absorption of zinc.

Population-Specific Caution

A critical, documented constraint applies to patients with undiagnosed Vitamin B12 deficiency. Folic Acid in doses above 0.1 mg daily is officially restricted in this condition because it can mask the hematologic symptoms while allowing the progression of neurological damage.

Mechanism of Action

How Folina Works — Mechanism of Action

The mechanism of Folic Acid, the active ingredient in Folina, is centered on its role as a fundamental metabolic precursor necessary for essential biochemical cycles, strictly regulating cell synthesis and proliferation.


Enzymatic Activation and One-Carbon Metabolism

Folic Acid is functionally activated by the enzyme Dihydrofolate Reductase (DHFR), converting it into Tetrahydrofolate (THF) cofactors. These cofactors are crucial for the One-Carbon Metabolism pathway, which facilitates vital methylation reactions, including the conversion of homocysteine to the amino acid methionine. This action supports the maintenance of regulated homocysteine levels.


Genetic Material Synthesis and Cell Proliferation

The active THF cofactors directly enable the de novo synthesis of purines and thymidylate, the building blocks of DNA and RNA. By providing these components, the mechanism supports the high-rate, orderly cell division required for proper cell maturation, thereby supporting the formation and maturation of red blood cells in the bone marrow.


Functional Interdependence and Mechanistic Limitations

The folate cycle is biochemically linked to Vitamin B12 (cobalamin), which is required to recycle the folate cofactors back into their active form. This functional interdependence imposes a constraint on the overall one-carbon metabolism cycle, as the required biochemical output is constrained if a deficiency in Vitamin B12 is simultaneously present.

Dosage and Administration Information

Folina (Folic Acid) is administered according to standardized regimens. The medication's primary method of intake is the oral route via tablets or capsules, as this is effective for the majority of individuals. Parenteral administration (intramuscular, intravenous, or subcutaneous injection) is an approved method used only in specific clinical scenarios, such as when severe malabsorption or inability to swallow prevents oral intake. Intravenous delivery, when necessary, is specified as a slow injection over at least one minute.

Dosing is strictly dependent on the medical purpose. For the treatment of megaloblastic anemia due to folate deficiency, the standard adult regimen is typically up to 1 mg once daily; however, doses up to 5 mg daily may be utilized to address severe malabsorption states. For the prophylactic prevention of Neural Tube Defects (NTDs) during pregnancy, the dose is generally 0.4 mg daily for average-risk individuals, increasing to 4 mg to 5 mg daily for those classified as high-risk.

The medication is commonly taken once daily and may be administered with or without food. For the correction of a diagnosed deficiency, the course duration is usually maintained until hematological parameters normalize, often taking approximately four months. Pediatric dosing for deficiency correction starts at similar initial doses, with adjustments based on the patient's weight or age. If a dose is missed, instructions advise skipping the missed dose and returning to the regular once-daily schedule, rather than taking a double dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Folina


Evidence for Use in Preventing Neural Tube Defects (NTDs)

Research examining the use of Folic Acid for the prevention of Neural Tube Defects (NTDs) was studied primarily through short-term Randomized Controlled Trials (RCTs) and observational cohorts. These studies were conducted globally, focusing on women of childbearing age during the periconceptional period. The primary outcomes measured by researchers included the incidence of Neural Tube Defects (NTDs) in newborns, along with maternal red blood cell folate concentrations.

Studies were designed to observe differences in the reported incidence of NTDs between groups receiving Folic Acid and those not receiving the supplement, and patterns were documented across these groups. Research consistently describes that studies monitored and tracked the elevation of maternal folate concentrations following supplementation, documenting a measurable biomarker response.

Evidence for Use in Treating Folate Deficiency Anemia

Research was conducted through a combination of Randomized Controlled Trials (RCTs), often historical, and observational cohorts examining the use of Folic Acid in individuals with confirmed megaloblastic anemia. The populations examined included adults and children with laboratory-confirmed anemia due to folate deficiency. The outcomes monitored were specific hematologic markers related to red blood cell production, such as hemoglobin levels, reticulocyte count, and the size of red blood cells.

Research highlights changes measured during the study period, where trials tracked sequential measurements of hematologic markers, documenting their evolution toward established reference ranges. Clinical observations were documented describing patterns of change in patient-reported outcomes related to symptoms, such as severe fatigue or chronic inflammation of the tongue (glossitis).

What is Still Uncertain in the Research Landscape

There is limited information regarding the sustained durability of physiological changes or outcomes over many years, as long-term effects are not fully established for many areas. The long-term clinical significance of correcting low folate biomarkers in an otherwise asymptomatic individual remains an area with limited data. Overall, evidence quality varies across studies, and certainty remains low regarding individualized predictions, as study results reflect the specific conditions under which they were conducted.

Key Studies & References

  1. Folic Acid for the Prevention of Neural Tube Defects: US Preventive Services Task Force Recommendation Statement
  2. Folic Acid Supplementation and the Risk of Cardiovascular Diseases: A Meta-Analysis of Randomized Controlled Trials (Homocysteine biomarker)
  3. Megaloblastic Anemia: What It Is, Symptoms, Causes & Treatment - Cleveland Clinic (Used for hematologic marker context in deficiency)
  4. Label: FOLIC ACID tablet - DailyMed (Used for regulatory context, B12 warning, and clinical pharmacology)

Frequently Asked Questions (FAQ)

Common questions about Folina (FAQ)


Q: How quickly does Folina typically start working?

A: Folic acid is absorbed quite quickly after an oral dose. Official information indicates the drug appears in the plasma (the liquid part of the blood) within 15 to 30 minutes, with peak levels reached in about an hour. For individuals taking Folina to correct a confirmed deficiency, subjective improvement in symptoms is sometimes noted as a pattern in the first 24 hours.


Q: How long does Folina stay in your system after stopping it?

A: Regulatory documents state that Folic Acid is eliminated primarily through the urine. The majority of the drug's metabolic products, which are the substances created as the body breaks down the drug, are typically excreted within 6 hours, and the process is generally complete within 24 hours.


Q: Is Folina the same thing as [Common similar drug name]?

A: The active ingredient in Folina is Folic Acid, which is a specific form of the B vitamin, also known as Vitamin B9. While Folic Acid belongs to a group of similar compounds called folates, other similar substances or derivatives have distinct chemical structures and names. Clarification of the specific ingredient and formulation may be necessary when comparing different products.


Q: What is the primary ingredient in Folina?

A: The primary active ingredient is Folic Acid. This substance is a B complex vitamin, and its chemical identity is precisely defined in official regulatory labeling. The full chemical name is N-[p-[[(2-amino-4-hydroxy-6-pteridinyl)methyl]-amino]benzoyl]-L-glutamic acid.


Q: Can Folina be taken if I have kidney problems?

A: Regulatory documents indicate that increased loss of folate may occur in individuals undergoing renal dialysis (kidney treatment). Official labels do not state a specific general restriction or required dose adjustment for mild to moderate kidney impairment. Regulatory oversight is typically required when Folina is used in populations with pre-existing kidney conditions.


Q: What is the main reason doctors prescribe Folina?

A: According to official product information, Folina is indicated to treat or prevent a folic acid deficiency, which can lead to certain types of anemia. It is also prescribed to individuals during the periconceptional period to prevent major birth defects of the brain and spinal cord, known as Neural Tube Defects (NTDs).


Q: Is Folina a vitamin or a prescription medicine?

A: Folic Acid is chemically classified as a B complex vitamin. However, the therapeutic strength formulations of Folina are sometimes classified under a Prescription Drug Label by the FDA. This classification allows the drug to be used specifically for treating diagnosed medical conditions.


Q: Is Folina safe for older adults?

A: Official regulatory labels often include specific sections for Geriatric Use. For Folic Acid, these sections do not contain unique restrictions or warnings compared to the general adult population. This indicates the absence of a distinct contraindication for the use of Folina in older adults documented in the labeling.


Q: What if I accidentally take two doses of Folina?

A: Regulatory warnings advise that taking amounts higher than the recommended dose can potentially cause adverse effects. Documented high-dose symptoms include confusion, nausea, irritability, and problems with sleeping. In cases of suspected overdose, patients are advised to seek immediate attention from a healthcare professional or a poison control center.


Q: Are there any warnings about driving or operating machinery while on Folina?

A: Although the official adverse reactions section lists psychiatric effects, such as confusion and impaired judgment, especially when taking high doses, explicit warnings about operating machinery or driving are not typically included on the drug's label.


Q: How is Folina eliminated from the body?

A: Folic Acid is eliminated primarily through the urine as a breakdown product. According to the regulatory information, this process begins soon after administration, with excretion being generally complete within 24 hours of taking a dose. Small amounts are also recovered in the feces.


Q: Can Folina be used during breastfeeding?

A: Official labels confirm that Folic Acid is naturally excreted into the breast milk of lactating mothers. While the nutritional requirement for Folic Acid increases during breastfeeding, the amounts present in human milk are noted as fulfilling infant requirements in most cases.


Q: Can men take Folina?

A: Folic acid is essential for the production of healthy cells and DNA synthesis, which is required by both men and women. The product's official constraints and warnings do not document restrictions specific to the male population. Folina is used by men primarily to treat folic acid deficiency.


Q: How can I find the official patient information leaflet for Folina?

A: The official patient information, often called the Prescribing Information or Label, can be accessed through governmental services. These documents reside on governmental services, including the DailyMed and FDA websites, and the NIH MedlinePlus Drug Information service.


Q: What is the chemical makeup of Folina?

A: The chemical makeup of Folic Acid is defined by its molecular formula, C19H19N7O6. Its precise structure allows it to function as a vitamin in the body's metabolic processes. The regulatory label provides the exact chemical name for the compound.


Q: Is Folina gluten-free or suitable for vegans?

A: The presence of gluten and other inactive ingredients, known as excipients, varies between different tablet and capsule formulations. Some regulatory documents note that specific low-dose products contain gluten from wheat starch and lactose. The inactive ingredients list on the product label should be reviewed by individuals with allergies or dietary restrictions.


Q: Does Folina require any special monitoring or follow-up blood tests?

A: Regulatory documents describe the need for clinical consideration to confirm Vitamin B12 status prior to Folic Acid administration. This is because Folic Acid can make the blood test results for B12 deficiency appear normal, allowing potentially serious neurological damage to progress unmasked.

How should Folina be stored and disposed of?

How to Store and Dispose of Folina

The storage and disposal of Folina (Folic Acid) must adhere strictly to the conditions specified in official regulatory labeling to ensure product quality and safety.

Storage Requirements

Folina must be stored under Controlled Room Temperature, typically not exceeding 25 C (77 F). The product must be protected from light and moisture and should be kept in the original package for stability. To prevent accidental ingestion, the medication must be stored out of the sight and reach of children and pets, often requiring a child-resistant closure on the container.

Disposal

Expired or unused Folina should not be thrown away via household waste or wastewater. Disposal must be carried out in accordance with local pharmaceutical requirements. Patients are advised to consult a pharmacist for instructions on how to safely discard the medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Folina found in:

A-Z Index: